|
|
|
Delaware
|
|
|
16-1630142
|
(State or other jurisdiction of
incorporation or organization)
|
|
|
(I.R.S. Employer
Identification No.)
|
|
Large accelerated filer
¨
|
Accelerated filer
¨
|
Non-accelerated filer
¨
(Do not check if a smaller reporting company)
|
Smaller reporting company
ý
|
Emerging growth company
¨
|
|
Title of Securities to be Registered
|
Amount to be Registered (1)
|
Proposed Maximum Offering Price per Share
|
Proposed Maximum Aggregate Offering Price
|
Amount of Registration Fee
|
Common Stock, $0.001 par value per share
|
691,648 (2)
|
$5.98 (3)
|
$4,136,055
|
$515
|
(1)
|
Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended, (the “Securities Act”) this Registration Statement shall also cover any additional shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”) that become issuable under the Apollo Endosurgery, Inc. 2017 Equity Incentive Plan (the "2017 Plan") by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Registrant's Common Stock.
|
(2)
|
Represents 691,648 additional shares of Common Stock reserved for future issuance under the 2017 Plan by reason of the annual increase provisions of the 2017 Plan. The number of shares reserved for issuance under the 2017 Plan will automatically increase on January 1st each year by the lesser of (a) an amount equity to four percent (4%) of the total number of shares of Common Stock outstanding on December 31st of the preceding calendar year, and (b) a lesser number determined by the Registrant's board of directors.
|
(3)
|
Estimated in accordance with Rules 457(c) and (h) solely for the purpose of calculating the registration fee on the basis of $5.98 per share, the average of the high and low prices of the Common Stock as reported on The Nasdaq Global market on March 2, 2018, a date that is within five business days prior to the date on which this Registration Statement is being filed.
|
Exhibit No.
|
|
Exhibit Description
|
|
Schedule / Form
|
|
File Number
|
|
Exhibit
|
|
Filing Date
|
4.1
|
|
|
8-K
|
|
001-35706
|
|
3.1
|
|
June 13, 2017
|
|
4.2
|
|
|
8-K
|
|
001-35706
|
|
3.2
|
|
June 13, 2017
|
|
4.3
|
|
|
10-Q
|
|
001-35706
|
|
4.1
|
|
May 4, 2017
|
|
5.1*
|
|
|
|
|
|
|
|
|
|
|
23.1*
|
|
|
|
|
|
|
|
|
|
|
23.2*
|
|
Consent of Cooley LLP (included in Exhibit 5.1)
|
|
|
|
|
|
|
|
|
24.1*
|
|
Power of Attorney (included on the signature page of this Form S-8)
|
|
|
|
|
|
|
|
|
99.1
|
|
|
8-K
|
|
001-35706
|
|
10.1
|
|
June 13, 2017
|
|
99.2
|
|
|
8-K
|
|
001-35706
|
|
10.2
|
|
June 13, 2017
|
|
99.3
|
|
|
8-K
|
|
001-35706
|
|
10.3
|
|
June 13, 2017
|
1.
|
The undersigned registrant hereby undertakes:
|
2.
|
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
3.
|
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
|
|
|
|
APOLLO ENDOSURGERY, INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Todd Newton
|
|
|
|
|
Name:
|
Todd Newton
|
|
|
|
|
Title:
|
Chief Executive Officer
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Todd Newton
|
|
Chief Executive Officer and Director
|
|
March 6, 2018
|
Todd Newton
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Stefanie Cavanaugh
|
|
Chief Financial Officer, Treasurer and Secretary
|
|
March 6, 2018
|
Stefanie Cavanaugh
|
|
(Principal Financial Officer)
|
|
|
|
|
|
|
|
/s/ Chrissy Citzler-Carr
|
|
Controller
|
|
March 6, 2018
|
Chrissy Citzler-Carr
|
|
(Principal Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Richard J. Meelia
|
|
Chairman of the Board
|
|
March 6, 2018
|
Richard J. Meelia
|
|
|
|
|
|
|
|
|
|
/s/ Rick Anderson
|
|
Director
|
|
March 6, 2018
|
Rick Anderson
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Matthew S. Crawford
|
|
Director
|
|
March 6, 2018
|
Matthew S. Crawford
|
|
|
|
|
|
|
|
|
|
/s/ John W. Creecy
|
|
Director
|
|
March 6, 2018
|
John W. Creecy
|
|
|
|
|
|
|
|
|
|
/s/ William D. McClellan, Jr.
|
|
Director
|
|
March 6, 2018
|
William D. McClellan, Jr.
|
|
|
|
|
|
|
|
|
|
/s/ R. Kent McGaughy, Jr.
|
|
Director
|
|
March 6, 2018
|
R. Kent McGaughy, Jr.
|
|
|
|
|
|
|
|
|
|
/s/ David C. Pacitti
|
|
Director
|
|
March 6, 2018
|
David C. Pacitti
|
|
|
|
|
|
|
|
|
|
/s/ Bruce Robertson, Ph.D.
|
|
Director
|
|
March 6, 2018
|
Bruce Robertson, Ph.D.
|
|
|
|
|
/s/ KPMG LLP
|
|
|
|
|
|
Austin, Texas
|
|
|
March 6, 2018
|
|
|